Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm currently has a $2.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 2.56% from the company’s current price.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.60 price objective (up previously from $6.50) on shares of Capricor Therapeutics in a report on Friday, January 26th.

Capricor Therapeutics (NASDAQ:CAPR) traded up $0.15 during mid-day trading on Tuesday, hitting $1.95. 918,396 shares of the company were exchanged, compared to its average volume of 639,093. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25. The firm has a market cap of $44.48, a PE ratio of -2.95 and a beta of -3.90.

Several hedge funds have recently added to or reduced their stakes in CAPR. Brown Advisory Inc. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter worth about $1,796,000. Virtu KCG Holdings LLC increased its holdings in shares of Capricor Therapeutics by 571.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 152,614 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Capricor Therapeutics in the 3rd quarter worth about $249,000. Jane Street Group LLC acquired a new stake in shares of Capricor Therapeutics in the 3rd quarter worth about $190,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Capricor Therapeutics in the 3rd quarter worth about $107,000. 4.05% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Capricor Therapeutics (CAPR) Raised to Buy at Zacks Investment Research” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2018/02/13/capricor-therapeutics-capr-raised-to-buy-at-zacks-investment-research.html.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.